Characteristics

Number (%)

Gender

Male

100 (46)

Female

116 (54)

Age

<40 years

24 (11)

Between 40 and 60 years

76 (35)

Between 60 and 80 years

108 (50)

>80 years

8 (4%)

TKI studied

Imatinib

69 (32)

Sunitinib

69 (32)

Sorafenib

22 (10)

Lapatinib

22 (10)

Pazopanib

15 (7)

Afatinib

11 (5)

Erlotinib

5 (2.5)

Regorafenib

2 (1)

Axitinib

1 (0.5)

TKI indications

Kidney cancer

78 (36)

GIST

71 (33)

Breast cancer

22 (10)

Lung cancer

16 (7.5)

thyroidcarcinoma

12 (5.5)

HCC

9 (4.5)

Others

8 (4)